Health TrialsbyHealthPanel

The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.

ConditionKidney Diseases
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age20-60
SponsorBispebjerg Hospital

About this trial

This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors.

The study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Normal health confirmed through; Interview and Medical examination

Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes

Informed consent

Disqualifiers

Immunosuppressive treatment in the previous 12 months

Alcohol abuse

Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism

Use of lithium

Trial design

Design model

Crossover

Treatments tested in this trial

  • Glucagon

    Drug

    Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes.

  • Glucagon+Exendin9-39

    Drug

    Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes

  • Sodium chloride

    Drug

    Placebo (0.9% NaCl).

Treatment groups

10 Participants
are divided into 3 treatment groups
Group A: GlucagonExperimental treatment 3 interventions
Group B: Glucagon+Exendin9-39Experimental treatment 3 interventions
Group C: Sodium chloride (Placebo comparator)Placebo comparator 3 interventions

Trial outcomes

Primary outcomes

1

Blood perfusion of the kidney

we would like to measure blood perfusion of the kidneys over time

Time frame
7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).

Secondary outcomes

1

Blood flow of the renal arteries

Time frame
7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
2

blood oxygen saturation of the kidneys

Time frame
7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Bispebjerg Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: